Abstract
PURPOSE OF REVIEW: The aim of this article was to review the recent literature on potential therapeutic strategies for overcoming resistance to antivascular endothelial growth factor drugs in ovarian cancer. RECENT FINDINGS: Although clinical benefits of antivascular endothelial growth factor therapy were observed in ovarian cancer treatment trials, this use yielded only modest improvement in progression-free survival and, with the exception of cediranib, no effect on overall survival. Adaptive resistance and escape from antiangiogenesis therapy is likely a multifactorial process, including induction of hypoxia, vascular modulators, and immune response. New drugs targeting the tumor vasculature or other components of the surrounding microenvironment have shown promising results. SUMMARY: When to start and end antiangiogenesis therapy and the choice of optimal treatment combinations remain controversial. Further evaluation of personalized novel angiogenesis-based therapy is warranted. Defining the critical interaction of these agents and pathways and the appropriate predictive markers will become an increasingly important objective for effective treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 58-65 |
Number of pages | 8 |
Journal | Current Opinion in Obstetrics and Gynecology |
Volume | 27 |
Issue number | 1 |
DOIs | |
State | Published - Feb 13 2015 |
Keywords
- adaptive resistance
- angiogenesis
- ovarian cancer
ASJC Scopus subject areas
- Obstetrics and Gynecology